(11th November, 2014); ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
[adsense:336x280:8701650588]